Marcela Valderrama Maus
2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston
ANNOUNCEMENT
Leaders in Pharmaceutical Business intelligence will cover in Real Time using Social Media this Event on CANCER Innovations
Aviva Lev-Ari, PhD, RN will be streaming LIVE from the Westin in Boston
worldmedicalinnovation.org
 |
| On behalf of Brigham and Women’s Hospital, Massachusetts General Hospital, and all of Partners HealthCare, we are pleased to invite you to the 2016 World Medial Innovation Forum. This unprecedented gathering will highlight the most promising approaches to diagnose, treat, and manage cancer and feature more than 100 speakers from throughout the top ranks of the global oncology community. For a complete list of our agenda and internationally recognized speakers, please visit the World Forum website. | ||
UPDATED on 4/13/2016
2016 WORLD MEDICAL INNOVATION FORUM TO FEATURE INNOVATIONS ENHANCING PATIENT CARE FROM PREVENTION TO THE NEEDS OF LONG-TERM CANCER SURVIVORS
BOSTON – April 13, 2016 – Partners HealthCare today announced that the upcoming World Medical Innovation Forum™ will include a focus on patient care, ranging from discussions of the importance of cancer prevention and early detection and the innovations that are making it possible to the unique care requirements and new technology approaches to help survivors. The 2016 Forum, an annual collaboration and partnering event held in Boston on April 25-27, will focus on cancer. CEOs and senior company executives, top investors, policy experts, and Harvard scientists leading the charge in the fight against cancer will take the stage over the course of the three-day Forum for a series of sessions that will critically examine the innovations in and evolution of cancer care.
“Technological advances in diagnostics are beginning to make it possible to detect cancer at the earliest stages of the disease when treatment may be most effective,” said David Louis, MD, Pathologist-in-Chief, Massachusetts General Hospital and Benjamin Castleman Professor of Pathology, Harvard Medical School. “However, there have been many barriers to making these innovative tests widely available to patients, including the need for more research and development to ensure accuracy, better guidance to speed the regulatory process and new models to support their value and reimbursement. This Forum provides a space for us to learn about these exciting new diagnostic technologies and to collaborate on the scientific and economic challenges that preventative strategies and early cancer detection bring about.”
“Detecting cancer as early as possible in the developmental stage will help both patients and hospitals in terms of prognosis with possible cure or therapy regimens before the cancer has spread. It will also help avoid the economic burden typically associated with late-stage detection,” said Massimo Loda, MD, Senior Pathologist, Brigham and Women’s Hospital, Principal Investigator, Dana-Farber Cancer Institute, and Professor of Pathology, Harvard Medical School. “The technologies we are creating and pursuing are designed to detect and pursue cancer cells at the most vulnerable point in their development: the very beginning. The Forum will provide us with the opportunity to discuss those advances and learn of other new developments in a collaborative manner.”
The prevention of cancer and the development of new strategies to detect cancer precursors and early-stage malignancies when treatment may be most effective – clinically and financially – are critical research goals. The experts on the “Early Detection and Prevention of Cancer” panel will review powerful imaging modalities, single-cell analysis of the tumor microenvironment and next-generation cancer models. They will also discuss circulating tumor DNA testing to monitor response to treatment and emergence of cancer resistance-with the objective of early cancer diagnosis before symptoms appear. The panel will take place at 4:50 p.m. on Monday, April 25, 2016, in the Novartis Ballroom of The Westin Copley Hotel.
Panel participants include:
- Moderator: David Louis, MD, Pathologist-in-Chief, MGH and Benjamin Castleman Professor of Pathology, Harvard Medical School
- Andy Chan, MD, Program Director, Gastroenterology Training Program, MGH and Associate Professor of Medicine, Harvard Medical School
- William Hait, MD, PhD, Global Head, Janssen Research & Development
- Krishna Kumar, CEO, Emerging Businesses, Philips
- Massimo Loda, MD, Senior Pathologist, Principal Investigator, BWH, Dana-Farber and Professor, Department of Pathology, Harvard Medical School
“The number of people diagnosed with cancer is continuing to grow at an astounding rate and while new treatment advances are enabling more and more of these patients to survive, there is an increasing need for innovative tools and resources to address the changing needs of patients, their families and the health care system,” said Claire Thom, Pharm D, Senior Vice President, Global Oncology Development, Astellas.
Extraordinary treatment advances have turned many cancers from apparent death sentences into manageable chronic illnesses with extraordinary consequences for the entire health care system. In the United States, there are approximately 14 million cancer survivors, up from just three million four decades earlier. Those survivors have unique care requirements, that will put enormous stress on the system and calling out for new technology solutions. A program, titled “Surviving Cancer: New Realities, New Needs,” will discuss those requirements and the technologies and approaches that can help monitor, guide, and connect patients. The panel will take place at 4:00 p.m. on Tuesday, April 26, 2016, in the Takeda Ballroom of The Westin Copley Hotel.
Panel participants include:
- Moderator: Tim Ferris, MD, Senior Vice President of Population Health Management, Partners HealthCare
- Jani Ahonala, CEO, Noona Healthcare
- Don Dizon, MD, Clinical Co-Director, Gynecologic Oncology, Founder and Director, The Oncology Sexual Health Clinic, MGH and Associate Professor of Medicine, Harvard Medical School
- Ann Partridge, MD, Director, Adult Survivorship Program, Program for Young Women with Breast Cancer, Dana-Farber and Associate Professor of Medicine, Harvard Medical School
- Claire Thom, Pharm D, Senior Vice President, Global Oncology Development, Astellas
Sponsors of the Forum include Novartis, Bristol-Myers Squibb, Takeda Oncology, Amgen, Astellas, AstraZeneca, General Electric, Ipsen, MacDougall Biomedical Communications, McCall & Almy, Mintz Levin, Ropes & Gray, and Vertex. STAT is the exclusive media partner of the Forum.
About the World Medical Innovation Forum
The World Medical Innovation Forum is a global gathering of senior corporate, investor, and academic leaders. It was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together and its ability to improve patient lives.
For more information or to register, please go to www.worldmedicalinnovation.org.
About Partners HealthCare
Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners HealthCare is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.
SOURCE
From: Kari Watson <contact@macbiocom.ccsend.com> on behalf of Kari Watson <wmif@macbiocom.com>
Reply-To: <wmif@macbiocom.com>
Date: Wednesday, April 13, 2016 at 10:59 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: World Medical Innovation Forum to Feature Innovations Enhancing Patient Care
|
AGENDA
Updated on 4/13/2016
MONDAY, APRIL 25, 2016
Ipsen Foyer
Ipsen Foyer
Takeda Ballroom
First Look: The Next Wave of Cancer Breakthroughs
Highly creative young investigators describe their most promising commercially
related research. Rapid-fire presentations by two dozen early-career Harvard
Medical School faculty will highlight compelling new discoveries and insights that
will be the cancer care products of the future. These young stars from Brigham and
Women’s Hospital, Massachusetts General Hospital and Dana-Farber Cancer
Institute will each describe their work in highly organized 10-minute sessions. This
session will take place in the Takeda Ballroom. Presenters will be available
immediately following their talk in the third floor GE Foyer.
Bristol-Myers Squibb Ballroom
Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare
Top Harvard Medical School faculty from Brigham and Women’s Hospital,
Massachusetts General Hospital and Dana-Farber Cancer Institute will host intimate
lunch discussions on developments in their field and their own research. These
internationally renowned leaders will engage on cutting edge research and new
trends in their clinical and research domain. Seating is reserved based on prior
registration. Please check at registration to find if there is open table availability.
A complete list of table hosts and topics is available here: http://worldmedicalinnovation.org/highlights/
Novartis Ballroom
Novartis Ballroom
A War or Moonshot: Where Do We Stand?
Forum Co-Chairs Dr. Bertagnolli and Haber provide perspectives on the coming era
of cancer research and care.
Novartis Ballroom
Creating a Disruptive Cancer Pipeline
Some companies characterize creating a successful pipeline of disruptive cancer
therapies as an engineering challenge, others describe arranging building blocks or
integrating capabilities from the marketplace – for many it is all of the above.
Considerations include discovering novel targets, novel single agent drugs and
emerging novel mechanisms, new pathways and/or mechanisms of action, new
molecular entities and technology acquisition strategies, among others. The panel,
corporate officers, investors and academic experts pulls back the curtain to discuss
the considerations in pipeline development, the tradeoffs and what it takes to
maintain success over time.
Novartis Ballroom
Curative Therapies: The Economics of Game Changing Science
Novel, potentially curative, cancer therapies are coming to market. Recent
experience in Hepatitis C therapy raises the question as to whether a new approach
is needed to design a pricing model that better balances resulting cost pressure
across the delivery system. While most acknowledge systemic cost effectiveness
curative therapies also present many challenges to payers – e.g. a spike in patient
volume and cost as these therapies are introduced. A broad ranging dialogue
has emerged in the cancer community that includes incorporating cost
effectiveness as part of the regulatory approval, shifting incentives for oncologists,
increasing emphasis on early detection, integrating billing codes, bundled
payments and management fees and many others. The panel with top executives
from the pharma, foundation, pharmacy and provider sectors will share insights on
this crucially important topic.
Novartis Ballroom
Winning Portfolio Strategy
The many considerations involved in managing a cancer portfolio are among the
most important for company vitality and also play a principal role in determining
the breadth and rate that new therapies reach patients. Considerations include
drug categories (current or potential), use of approved drugs on new tumor
types, product life extension, concentrating on call point strengths vs broadening
into new cancers, technology category strength – e.g. small molecule vs emerging
ones like CAR-T, product lifecycle status, competitive agents, possible portfolio
swaps (e.g. NVS/GSK) and shareholder scrutiny . Panel members from the highest
ranks of the industry — large and emerging companies — will discuss their strategic
approach to balancing considerations they can influence and those that they can’t.
Novartis Ballroom
Early Detection and Prevention of Cancer
The prevention of cancer and the development of new strategies to detect cancer
precursors and early-stage malignancies when treatment may be most effective
– clinically and financially — are critical research goals. Our panel of experts reviews
powerful imaging modalities, single-cell analysis of the tumor microenvironment
and next-generation cancer models. Circulating tumor DNA testing to monitor
response to treatment and emergence of cancer resistance—with the objective of
early cancer diagnosis before symptoms appear—will also be detailed.
Novartis Ballroom
Takeda Ballroom
Bristol-Myers Squibb Ballroom
Ropes & Gray Dinner Program – Fireside Chat: Richard Gonzalez, CEO, AbbVie
TUESDAY, APRIL 26, 2016
Ipsen Foyer
Novartis Ballroom
Global Cancer Markets
Cancer causes 1 in 7 deaths worldwide. If rates don’t change, the global cancer
burden is expected to increase from 14 million new cases and 8 million cancer
related deaths worldwide to 22 million cases and 13 million deaths by 2030. The
panel will discuss how approaches to deliver innovative technologies differ in
different international markets, what the respective drivers are, as well as
requirements and challenges. Expert panelists from leading international
companies and key governmental entities, including the famed NICE from the UK
NHS, will consider strategies and key trends.
Novartis Ballroom
Epigenetics and Novel Cancer Targets
The initiation and progression of cancer is controlled by both genetic and
epigenetic events. Epigenetics, the study of changes that influence how DNA
does its job, is one of the fastest-moving fields in cancer research. Expert corporate
and academic panel members will discuss the promise of epigenetics. They will
describe translating basic epigenetic research into cancer diagnostics and
therapies, emphasizing market opportunities and competitive advantages.
Ipsen Foyer
Novartis Ballroom
Novartis Ballroom
Immunotherapy I: Checkpoint Activation and Cancer Vaccines
Among the most promising approaches to activating therapeutic antitumor
immunity is the blockade of immune checkpoints. Checkpoint blockade, prevention
of inhibitory signaling that limits activation or function of tumor antigen-specific
T cells responses, is revolutionizing the treatment of many poor-prognosis
malignancies. Expert panelists discuss significant long-term cancer remissions,
potential cures – in some cases – and how boosting the body’s own defenses
is producing stunning results when combined with standard anticancer therapies
and other immunotherapies. They will also detail the experimental accines in
development that are designed to “wake up” the immune system so it will trigger
reliable and effective attacks on cancer cells.
Bristol-Myers Squibb Ballroom
Bristol-Myers Squibb Ballroom
Fireside Chat: Andy Slavitt, Acting Administrator, CMS
Bristol-Myers Squibb Ballroom
Fireside Chat: Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
Novartis Ballroom
Novartis Ballroom
Immunotherapy II: Cell Based Therapies
Oncology sits on the cusp of a new revolution thanks to the use of human cells as versatile
therapeutic engines. By modifying T cells to express chimeric antigen receptors (CARs) that
recognize cancer-specific antigens, our expert panelists describe how they have been able to prime
cells to recognize and kill tumor cells that would otherwise escape immune detection. They also
detail the various “living drugs” that kill cancer cells and could replace standard oncology
treatments in the future.
Novartis Ballroom
Financing Breakthrough Cancer Companies
The global market for oncology therapies is currently more than $100 billion annually, and could
reach $147 billion by the end of the decade. Panel experts discuss the most compelling
technologies, trends driving investment considerations, new models, pricing considerations and
strategies they use as leading oncology investors in both early stage and established companies.
Astellas Ballroom
Arms Race in Radiation
The Holy Grail of radiation therapy is to maximize the effectiveness of killing cancer
cells while minimizing the effect on neighboring tissue. Technology meets modern
cancer care with the integration of technologies that offer enormous benefits to
the cancer patient in improved quality of life and increased likelihood of
cure. Expert panelists will highlight current benefits of radiation therapies, the
increasing use of hypofractionated radiation therapy and describe future tools in
development that will have the potential to dramatically improve outcomes.
Bristol-Myers Squibb Ballroom
Breakthrough Devices to Treat Cancer
The increasing demand for early diagnosis of cancer and the growing prevalence of
metastatic brain, lung, breast, prostate and other cancers is driving the oncology
device market. Our experts zero in on innovative technologies that will address
challenges in cancer surgery and pain management.
Novartis Ballroom
Study Designs to Meet the Challenges of Personalized Cancer Medicine
Cancer biology indicates that cancer is a large number of niche diseases that may be targeted
with therapies against specific molecular alterations common to multiple tumor types. This
model creates challenges for both drug development and patient care with implications for
initial indication selection and design and execution of clinical trials – from first in human
through post marketing studies. Among the topics the panel will address:
• The availability of biomarkers to stratify trials, select patients and monitor drug response can improve
both trial speed and cost, as well as enable development of companion diagnostics but at the same time
present more complex validation requirements.
• Design of trials using surrogate end points holds great promise but validation of such endpoints is a
regulatory challenge. Adaptive trial designs for dose response, pK/PD and efficacy hold promise but
adoption of such approaches has been slow.
• Cancer immunotherapies create a significant opportunity for development of combination therapies
but the cost of acquiring the approved drug can significantly increase the cost of clinical trials. This may
necessitate new approaches to late preclinical development as well as biomarkers that are early and
accurate indicators of drug response for incorporation in the clinical trial in Phase I/II.
• The cost of current and next generation cancer drugs will require measuring clinical and econometric
outcomes in order to justify reimbursement. This may mandate larger post marketing clinical studies,
including observational trials
Takeda Ballroom
Surviving Cancer: New Realities, New Needs
Extraordinary treatment advances have turned many cancers from apparent death sentences
into manageable chronic illnesses with extraordinary consequences for the entire health
care system. In the United States, there are approximately 14 million cancer survivors, up from
just three million four decades ago. Those survivors have unique care requirements, that will
put enormous stress on the system — calling out for new technology solutions. The panel will
discuss requirements technologies and approaches that can help monitor, guide, and connect
patients.
General Electric Foyer
WEDNESDAY, APRIL 27, 2016
Ipsen Foyer
Novartis Ballroom
Combination Cancer Therapies: Drug Resistance and Therapeutic Index
Study Designs to Meet the Challenges of Personalized Cancer Medicine Game changing modern
cancer therapies—immunotherapies and targeted therapies, among others—do not by themselves
meet the needs of many patients who require alternative strategies to achieve optimal therapeutic
benefit. Panel experts will describe combining these therapies with other drugs, challenges and the
path forward.
Novartis Ballroom
Novartis Ballroom
Cancer Diagnostics: New Uses, New Reimbursements?
Advances in genetics, genomics and proteomics are driving advances in identifying and treating
disease. Use of genetic testing and molecular diagnostics is rapidly expanding in clinical practice,
creating a new, personalized approach to medicine. Panelists describe key new technologies and
how they will be fully integrated into the delivery of care.
Novartis Ballroom
New Philanthropy: Patients Driving Innovation
Philanthropy’s role in driving improved cancer care has evolved rapidly over the
last decade. Disease foundations have become active in nearly every phase of the
care spectrum supporting innovations in the lab, clinic, patient engagement, and
regulatory approval among others. Senior philanthropic leaders will describe how
the foundation community is redefining roles and finding new ways to help
patients as they seek to drive breakthroughs in understanding and care.
Novartis Ballroom
Disruptive Dozen
Cancer faculty from the Brigham and Women’s Hospital, Massachusetts General
Hospital, and Dana-Farber Cancer Institute nominated dozens of technologies that
will have the greatest impact on cancer care in the next decade, and then compiled
a ranking of the 12 most disruptive technologies. A panel of experts will announce
and discuss each of the technologies chosen. This intriguing, informative and fun
session will let you in on how the experts view the future in their field.
Ipsen Foyer
Novartis Ballroom
SOURCE
From: Kari Watson <contact@macbiocom.ccsend.com> on behalf of Kari Watson <wmif@macbiocom.com>
Reply-To: <wmif@macbiocom.com>
Date: Wednesday, April 13, 2016 at 10:59 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: World Medical Innovation Forum to Feature Innovations Enhancing Patient Care
2012pharmaceutical
sjwilliamspa